R. Triolo

PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy

M. Barbareschi, S. Girlando, E. Galligioni, 2012, Virchows Archiv.

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

R. Danesi, O. Goletti, M. Scalese, 2014, Pharmacogenomics.

In a cohort of breast cancer screened patients the proportion of HER2 positive cases is lower than that earlier reported and pathological characteristics differ between HER2 3+ and HER2 2+/Her2 amplified cases

C. Luchini, M. Barbareschi, M. Pellegrini, 2016, Virchows Archiv.

PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy

A. Marchetti, F. Buttitta, M. Seckl, 2013, Virchows Archiv.